Prostate cancer for experts
May 17th - November 16th 2023
Aimed at:
Residents 4th and 5th year of Urology
4th year of O. Radiation therapy
4th and 5th year O. Medical
Associates of related specialties
COORDINATORS
Iván Henríquez López
Hospital Universitario Sant Joan, Reus
Oncology Radiation therapy.
Jesús Muñoz
Hospital Parc Tauli, Sabadell
Urology Service.
Enrique Gallardo
Hospital Parc Tauli, Sabadell
Medical Oncology Service.
FACULTY
Jaques Planas
María Isabel Chirivella
Marta Barrado
Digna Pachuca
Ángel Borque
Manuel Altabas
Asunción Hervás
Oscar Buisan
Luis Glaria Enriquez
Rafael García
Rodríguez Melcón
Enrique Sánchez Aparicio
Martínez Ballesteros
Alvaro Pinto
Felipe Couñago
Antonio Gómez Caamaño
Carmen González San Segundo
Antonio Conde Moreno
Fernando López Campos
David Buchse
Alejo Rodríguez-Vida
Ana Plata
Caterina Aversa
COURSE STRUCTURE
SECTION 1 - May 17th
From the basics to the clinical in prostate cancer
1.1. Functional anatomy of prostate cancer. – Urology. – Dr. J. Planas. H. Vall d’Hebron. Barcelona
1.2. Staging of prostate cancer. – O. Medicine – Dra. María Isabel Chirivella. H. La Fe. Valencia
1.3. Clinical prognostic factors in prostate cancer. – O. Radiation therapy – Dra. Marta Barrado. Complejo Hospitalario de Navarra. Pamplona
1.4. Use of conventional images and molecular in prostate cancer. – Radiology – Dra. Digna Pachuca. (México)
1.5. Screening and active surveillance. Current situation. – Urology – Dr. Ángel Borque. H. Miguel Servet. Zaragoza
SECTION 2 - June 14th
Standard treatment in prostate cancer
2.1. Radical prostatectomy. Techniques and indications. – Urology – Por definir
2.2. Dose Intensification of External Radiation Therapy with or without androgen deprivation. – O. Radiation therapy – Dr. Manuel Altabas. H. Vall d’ Hebron. Barcelona
2.3. Moderate hypofractionation in prostate cancer. – O. Radiation therapy – Dra. Asunción Hervás. Fundación Jimenez Díaz. Madrid
2.4. Toxicity and quality of life of prostatectomy radical. – Urology – Dr. Oscar Buisan. H. Germans Trias i Pujol. Badalona
2.5. Toxicity and quality of life of external radiation therapy and androgen deprivation. – O. Radiation therapy – Dr. Luis Glaria Enriquez. H. La Paz. Madrid
SECTION 3 - July 12th
Specific treatments in prostate can
3.1. SBRT in prostate cancer. – O. Radiation therapy – Dr. Rafael García . H. Ruber Internacional. Madrid
3.2. Brachytherapy treatment (monotherapy) in prostate cancer. – O. Radiation therapy – Dr. Rodríguez Melcón. H. Negrín. Canarias
3.3. Clinical management (cN0) in high risk prostate cancer. – O. Radiation therapy – Dr. Enrique Sánchez Aparicio. H. León. Castilla y León
3.4. Clinical management (cN1 and pN1) in prostate cancer. – Urology – Dr. Martínez Ballesteros. H. Puerta Hierro. Madrid
3.5. Adjuvant chemotherapy in high-risk prostate cancer. – O. Medical – Dr. Alvaro Pinto. H. La Paz. Madrid
SECTION 4 - August 9th
Special situations in prostate cancer
4.1. Genomic platforms in prostate cancer. – O. Radiation therapy – Dr. Felipe Couñago. H. Quirón Salud. Madrid
4.2. Adjuvant radiation therapy and rescue radiation therapy. – O. Radiation therapy – Dr. Antonio Gómez Caamaño. H. Santiago de Compostela. Galicia
4.3. Biochemical recurrence after radiotherapy. Treatment alternatives. – O. Radiation therapy – Dra. Carmen González San Segundo. H. Gregorio Marañón. Madrid
4.4. Oligometastatic prostate cancer. Concepts and therapeutic approach. – O. Radiation therapy – Dr. Antonio Conde Moreno. IVO. Valencia
4.5. Genomic markers in prostate cancer. – O. Radiation therapy – Dr. Fernando López Campos. Fundación Jimenez Díaz. Madrid
SECTION 5 - September 6th
New perspectives in advanced prostate cancer
5.1. Importance of local treatment in CaP hormone-sensitive metastatic. – O. Radiation therapy – Dr. David Buchser. H. Cruces. Bilbao
5.2. Hormone-sensitive metastatic prostate cancer (CPHSm). Systemic management. – O. Medical – Dr. Alejo Rodríguez-Vida. H. del Mar. Barcelona
5.3. Non-metastatic high-risk castration-resistant prostate cancer (CPRCM0). – Urology – Dra. Ana Plata. H. Tenerife. Canarias
5.4. Metastatic castration-resistant prostate cancer (CPRCM1). – O. Medical – Dra Caterina Aversa. H. Clínic. Barcelona
5.5. Future of Prostate Cancer. – Drs course Coordinators
REGISTRATION
CONTACT
Aventik Medical S.L.U.
Tel. 685265622
info@aventik.es